Stephen Hahn is Commissioner of the Food & Drug Administration when this happens.
An exception is made for treating hospital patients.
The rationale for this action is based on the Surgisphere studies that were retracted on June 2, 2020. The retraction took place prior to the date of the revocation of EUA for HCQ. This appears to be an instance of “Wrap Up” Smear.
Had an Emergency Use Authorization ever been issued for Chloroquine and Hydroxychloroquine for the FDA to revoke?
Has an EUA ever before been issued for an approved drug?
Sources:
- June 16, 2020. US Food & Drug Administration. “Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine.”
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.
Food & Drug Administration. - April 18, 2019. US Food & Drug Administration. “Understanding Unapproved Use of Approved Drugs ‘Off Label.’”
https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label.
Food & Drug Administration. - July 9, 2021. Claire Chretien [LifeSiteNews]. Dr. Zelenko: “Life Saving Information…Is Being Criminally Suppressed” by Big Pharma. Runtime: 17:00.
https://rumble.com/vjnael-dr.-zelenko-life-saving-information…is-being-criminally-suppressed-by-big.html.
Video, Expert.
See also, on this site:
- FDA grants approval for Plaquenil (hydroxychloroquine sulfate, aka HCQ)
- Virology Journal: “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”
- Rep. Nancy Pelosi explains the “Wrap Up” Smear.
- Two medical journals retract study submitted by Surgisphere after company called into question.
- All posts citing the 7 July 2021 interview between LifeSiteNews and Dr. Zelenko, clip on Big Pharma criminal suppression
There never should have been a need for an Emergency Use Authorization for Hydroxychloroquine. HCQ was approved by the FDA in 1955. Preventing or treating COVID-19 are not labeled uses, but that should not prevent practitioners from prescribing it. The off-label use policy allows practitioners to prescribe as they deem appropriate.